Companies ›Healthcare ›AMRX

AMRX — Nasdaq Pharmaceuticals

Amneal Pharmaceuticals, Inc.

$18,85

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

6,2B USD

P/E

84,5x

EV / Rev

2,8x

Div yield

—

Op margin

13,1 %

ROE

-158,7 %

Net margin

2,4 %

Debt / equity

-56,63

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$18,50

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Amneal Pharmaceuticals, Inc. is classified under Healthcare / Pharmaceuticals and appears profitable on the latest normalized snapshot.

Business. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a healthcare company operating in the pharmaceuticals industry. The firm engages in pharmaceutical activities with a product-sale revenue model. Specific details regarding operating segments and geographic mix are not provided. The company is primarily listed on the Nasdaq exchange.

Classification98 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · rules-based

Sell-side consensus

BUY5 analysts

5 buy0 hold0 sell

Avg 12m price target20,04

Analyst recommendations

5 analysts · consensus Buy

Buy5

Hold0

Sell0

12-month price target

20,04

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

5 analysts · indicative

Ownership→

Dimensional Fund Advisors, L.P.

largest disclosed fund holder

Profitability→

-158,7 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning AMRX.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to AMRX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a healthcare company operating in the pharmaceuticals industry. The firm engages in pharmaceutical activities with a product-sale revenue model. Specific details regarding operating segments and geographic mix are not provided. The company is primarily listed on the Nasdaq exchange.

Classification98 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

Amneal Pharmaceuticals, Inc. (AMRX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on the latest snapshot: total assets 3,540,218,000 USD, total equity -45,411,000, short-term debt 6,200,000, long-term debt 2,565,558,000. Net cash position is approximately -2,374,102,000 USD. Self-calculated market cap is 6,085,260,500 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 722,519,000, gross profit 320,113,000, operating income 141,772,000, net income 62,256,000. Return on equity ~-158.7%. Return on assets ~2.0%. Operating-cash-flow to net-income ratio is 4.72. Risk profile from automated assessment: liquidity risk medium, dilution risk medium. Flags: Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on AMRX — filing_type=8-K; max_severity=medium; ignored_items=['7.01', '9.01']; material_items=['2.02']; all_items_found=['2.02', '7.01', '9.01']; severity_per_code={'2.02': 'medium'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001723128-26-000025). Additional context: 8-K: filing_type=8-K; max_severity=medium; ignored_items=['7.01', '9.01']; material_items=['2.02']; all_items_found=['2.02', '7.01', '9.01']; severity_per_code={'2.02': 'medium'}; contributing_watchers=sec_8k_material.

Key takeaways

Observed GAAP P/E is about 84.45x.
Return on equity is about -158.7%.
Debt to equity is about -56.63x.
[TRIGGER] 8-K: 8-K (sec_8k_material) on AMRX — filing_type=8-K; max_severity=medium; ignored_items=['7.01', '9.01']; material_items=['2.02']; all_items_found=['2.02', '7.01', '9.01']; severity_per_code={'2.02': 'medium'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001723128-26-000025)
Companyfacts coverage was partial; recent filing facts backfilled accounts_payable.
amrx-20260331 0001723128 12-31 2026 Q1 false http://fasb.org/us-gaap/2025#OtherOperatingIncomeExpenseNet http://fasb.org/us-gaap/2025#OtherOperatingIncomeExpenseNet xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure amrx:state amrx:complaint amrx:case iso4217:USD amrx:twinPack amrx:segment 0001723128 2026-01-01 2026-03-31 0001723128 2026-04-30 0001723128 2025-01-01 2025-03-31 0001723128 2026-03-31 0001723128 2025-12-31 0001723128 us-gaap:NonrelatedPartyMember 2026-03-31 0001723128 us-gaap:NonrelatedPartyMember 2025-12-31 0001723128 us-gaap:RelatedPartyMember 2026-03-31 0001723128 us-gaap:RelatedPartyMember 2025-12-31 0001723128 us-gaap:CommonClassAMember 2025-12-31 0001723128 us-gaap:CommonClassAMember 2026-03-31 0001723128 us-gaap:CommonClassBMember 2026-03-31 0001723128 us-gaap:CommonClassBMember 2025-12-31 0001723128 2024-12-31 0001723128 2025-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-12-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001723128 us-gaap:RetainedEarningsMember 2025-12-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001723128 us-gaap:NoncontrollingInterestMember 2025-12-31 0001723128 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001723128 us-gaap:RetainedEarningsMember 2026-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2026-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001723128 us-gaap:RetainedEarningsMember 2024-12-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001723128 us-gaap:NoncontrollingInterestMember 2024-12-31 0001723128 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001723128 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-03-31 0001723128 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001723128 us-gaap:RetainedEarningsMember 2025-03-31 0001723128 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001723128 us-gaap:NoncontrollingInterestMember 2025-03-31 0001723128 amrx:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0001723128 amrx:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0001723128 amrx:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0001723128 amrx:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0001723128 amrx:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-03-31 0001723128 amrx:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-31 0001723128 amrx:OralSolidMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:OralSolidMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:TransdermalMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:TransdermalMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:InjectableMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:InjectableMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:EphinephrineAutoInjectorMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:EphinephrineAutoInjectorMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:BiosimilarMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:BiosimilarMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:OralLiquidMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:OralLiquidMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:OtherDosageFormsMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:OtherDosageFormsMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:SubtotalDosageFormsMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:SubtotalDosageFormsMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:InternationalMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:InternationalMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 amrx:CentralNervousSystemMember amrx:SpecialtySegmentMember 2026-01-01 2026-03-31 0001723128 amrx:CentralNervousSystemMember amrx:SpecialtySegmentMember 2025-01-01 2025-03-31 0001723128 amrx:HormonalAllergyMember amrx:SpecialtySegmentMember 2026-01-01 2026-03-31 0001723128 amrx:HormonalAllergyMember amrx:SpecialtySegmentMember 2025-01-01 2025-03-31 0001723128 amrx:OtherTherapeuticClassesMember amrx:SpecialtySegmentMember 2026-01-01 2026-03-31 0001723128 amrx:OtherTherapeuticClassesMember amrx:SpecialtySegmentMember 2025-01-01 2025-03-31 0001723128 amrx:SubtotalTherapeuticClassesMember amrx:SpecialtySegmentMember 2026-01-01 2026-03-31 0001723128 amrx:SubtotalTherapeuticClassesMember amrx:SpecialtySegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:DistributionServiceMember amrx:AvKARESegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:DistributionServiceMember amrx:AvKARESegmentMember 2025-01-01 2025-03-31 0001723128 amrx:GovernmentLabelMember amrx:AvKARESegmentMember 2026-01-01 2026-03-31 0001723128 amrx:GovernmentLabelMember amrx:AvKARESegmentMember 2025-01-01 2025-03-31 0001723128 amrx:InstitutionalMember amrx:AvKARESegmentMember 2026-01-01 2026-03-31 0001723128 amrx:InstitutionalMember amrx:AvKARESegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:ProductAndServiceOtherMember amrx:AvKARESegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:ProductAndServiceOtherMember amrx:AvKARESegmentMember 2025-01-01 2025-03-31 0001723128 amrx:AvKARESegmentMember 2026-01-01 2026-03-31 0001723128 amrx:AvKARESegmentMember 2025-01-01 2025-03-31 0001723128 amrx:ContractChargebacksAndSalesVolumeAllowancesMember 2025-12-31 0001723128 amrx:CashDiscountAllowancesMember 2025-12-31 0001723128 us-gaap:SalesReturnsAndAllowancesMember 2025-12-31 0001723128 amrx:AccruedMedicaidAndCommercialRebatesMember 2025-12-31 0001723128 amrx:ContractChargebacksAndSalesVolumeAllowancesMember 2026-01-01 2026-03-31 0001723128 amrx:CashDiscountAllowancesMember 2026-01-01 2026-03-31 0001723128 us-gaap:SalesReturnsAndAllowancesMember 2026-01-01 2026-03-31 0001723128 amrx:AccruedMedicaidAndCommercialRebatesMember 2026-01-01 2026-03-31 0001723128 amrx:ContractChargebacksAndSalesVolumeAllowancesMember 2026-03-31 0001723128 amrx:CashDiscountAllowancesMember 2026-03-31 0001723128 us-gaap:SalesReturnsAndAllowancesMember 2026-03-31 0001723128 amrx:AccruedMedicaidAndCommercialRebatesMember 2026-03-31 0001723128 us-gaap:ResearchAndDevelopmentExpenseMember amrx:LicenseAgreementWithOrionCorporationMember 2026-01-01 2026-03-31 0001723128 us-gaap:ResearchAndDevelopmentExpenseMember amrx:LicenseAgreementWithOrionCorporationMember 2025-01-01 2025-03-31 0001723128 amrx:ReimbursableResearchAndDevelopmentMember amrx:LicenseAgreementWithOrionCorporationMember 2026-01-01 2026-03-31 0001723128 amrx:ReimbursableResearchAndDevelopmentMember amrx:LicenseAgreementWithOrionCorporationMember 2025-01-01 2025-03-31 0001723128 us-gaap:OtherOperatingIncomeExpenseMember amrx:LicenseAgreementWithPfizerIncMember 2026-01-01 2026-03-31 0001723128 us-gaap:OtherOperatingIncomeExpenseMember amrx:LicenseAgreementWithPfizerIncMember 2025-01-01 2025-03-31 0001723128 amrx:LicenseAgreementWithOrionCorporationMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2026-03-31 0001723128 amrx:LicenseAgreementWithOrionCorporationMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2025-12-31 0001723128 amrx:LicenseAgreementWithOrionCorporationMember us-gaap:OtherNoncurrentLiabilitiesMember 2026-03-31 0001723128 amrx:LicenseAgreementWithOrionCorporationMember us-gaap:OtherNoncurrentLiabilitiesMember 2025-12-31 0001723128 amrx:LicenseAgreementWithZambonBiotechMember us-gaap:OtherNoncurrentLiabilitiesMember 2026-03-31 0001723128 amrx:LicenseAgreementWithZambonBiotechMember us-gaap:OtherNoncurrentLiabilitiesMember 2025-12-31 0001723128 amrx:MAbxienceS.L.AgreementMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2026-03-31 0001723128 amrx:MAbxienceS.L.AgreementMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2025-12-31 0001723128 amrx:LicenseAgreementWithPfizerIncMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2026-03-31 0001723128 amrx:LicenseAgreementWithPfizerIncMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2025-12-31 0001723128 amrx:LicenseAgreementWithPfizerIncMember us-gaap:OtherNoncurrentLiabilitiesMember 2026-03-31 0001723128 amrx:LicenseAgreementWithPfizerIncMember us-gaap:OtherNoncurrentLiabilitiesMember 2025-12-31 0001723128 amrx:LicenseAgreementWithPfizerIncMember 2025-01-01 2025-12-31 0001723128 amrx:LicenseAgreementWithPfizerIncMember 2025-12-31 0001723128 amrx:PfizerArrangementMember 2026-01-29 2026-01-29 0001723128 amrx:PfizerArrangementMember 2026-01-30 2026-01-30 0001723128 amrx:PfizerArrangementMember amrx:LicenseAgreementWithPfizerIncMember 2026-03-31 0001723128 amrx:PfizerArrangementMember amrx:LicenseAgreementWithPfizerIncMember 2026-01-01 2026-03-31 0001723128 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001723128 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001723128 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001723128 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001723128 us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001723128 us-gaap:PerformanceSharesMember 2025-01-01 2025-03-31 0001723128 amrx:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-01-01 2026-03-31 0001723128 amrx:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-12-31 0001723128 amrx:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-01-01 2026-03-31 0001723128 amrx:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-12-31 0001723128 amrx:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-01-01 2026-03-31 0001723128 amrx:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-12-31 0001723128 amrx:GenericsSegmentMember 2024-12-31 0001723128 amrx:AmnealSpecialtyPharmaSegmentMember 2024-12-31 0001723128 amrx:AvKARESegmentMember 2024-12-31 0001723128 amrx:GenericsSegmentMember 2025-01-01 2025-12-31 0001723128 amrx:AmnealSpecialtyPharmaSegmentMember 2025-01-01 2025-12-31 0001723128 amrx:AvKARESegmentMember 2025-01-01 2025-12-31 0001723128 2025-01-01 2025-12-31 0001723128 amrx:GenericsSegmentMember 2025-12-31 0001723128 amrx:AmnealSpecialtyPharmaSegmentMember 2025-12-31 0001723128 amrx:AvKARESegmentMember 2025-12-31 0001723128 amrx:GenericsSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:AmnealSpecialtyPharmaSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:GenericsSegmentMember 2026-03-31 0001723128 amrx:AmnealSpecialtyPharmaSegmentMember 2026-03-31 0001723128 amrx:AvKARESegmentMember 2026-03-31 0001723128 us-gaap:ContractualRightsMember 2026-03-31 0001723128 us-gaap:ContractualRightsMember 2025-12-31 0001723128 us-gaap:TradeNamesMember 2026-03-31 0001723128 us-gaap:TradeNamesMember 2025-12-31 0001723128 us-gaap:InterestRateSwapMember 2026-03-31 0001723128 us-gaap:InterestRateSwapMember 2025-12-31 0001723128 amrx:SecurityDepositsMember 2026-03-31 0001723128 amrx:SecurityDepositsMember 2025-12-31 0001723128 amrx:LongTermPrepaidExpensesMember 2026-03-31 0001723128 amrx:LongTermPrepaidExpensesMember 2025-12-31 0001723128 amrx:DeferredRevolvingCreditFacilityCostsMember 2026-03-31 0001723128 amrx:DeferredRevolvingCreditFacilityCostsMember 2025-12-31 0001723128 amrx:LongTermRestrictedCashMember 2026-03-31 0001723128 amrx:LongTermRestrictedCashMember 2025-12-31 0001723128 us-gaap:OtherNoncurrentAssetsMember 2026-03-31 0001723128 us-gaap:OtherNoncurrentAssetsMember 2025-12-31 0001723128 amrx:TermLoanDue2032Member amrx:TermLoanMember 2026-03-31 0001723128 amrx:TermLoanDue2032Member amrx:TermLoanMember 2025-12-31 0001723128 amrx:SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2026-03-31 0001723128 amrx:SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2025-12-31 0001723128 amrx:TermLoanDue2032Member amrx:TermLoanMember 2026-02-02 2026-02-02 0001723128 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember amrx:TermLoanDue2032Member amrx:TermLoanMember 2026-02-02 2026-02-02 0001723128 us-gaap:BaseRateMember amrx:TermLoanDue2032Member amrx:TermLoanMember 2026-02-02 2026-02-02 0001723128 amrx:TermLoanDue2032Member amrx:TermLoanMember 2026-01-01 2026-03-31 0001723128 us-gaap:InterestRateContractMember 2026-03-31 0001723128 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0001723128 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0001723128 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001723128 us-gaap:InterestRateContractMember 2025-12-31 0001723128 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0001723128 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0001723128 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001723128 us-gaap:FairValueInputsLevel2Member amrx:TermLoanDue2032Member amrx:TermLoanMember 2026-03-31 0001723128 us-gaap:FairValueInputsLevel2Member amrx:TermLoanDue2032Member amrx:TermLoanMember 2025-12-31 0001723128 us-gaap:FairValueInputsLevel2Member amrx:SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2026-03-31 0001723128 us-gaap:FairValueInputsLevel2Member amrx:SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2025-12-31 0001723128 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-03-31 0001723128 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-03-31 0001723128 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0001723128 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-12-31 0001723128 amrx:VariableToFixedInterestRateSwapMember us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-31 0001723128 amrx:VariableToFixedInterestRateSwapMember us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2026-03-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2025-12-31 0001723128 amrx:OtherMember 2026-03-31 0001723128 amrx:OtherMember 2025-12-31 0001723128 amrx:UnitedStatesDepartmentOfJusticeInvestigationsMember 2023-05-15 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2020-12-31 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2019-12-31 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2020-01-01 2020-12-31 0001723128 amrx:GenericDigoxinAndDoxycyclineAntitrustLitigationMember 2019-01-01 2019-12-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2026-02-25 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2026-02-26 0001723128 amrx:CivilPrescriptionOpioidsSettlementAgreementMember 2026-01-23 2026-01-23 0001723128 amrx:CivilPrescriptionOpioidsSettlementAgreementMember 2026-02-26 2026-02-26 0001723128 amrx:LitigationSettlementOptionOneMember amrx:CivilPrescriptionOpioidLitigationMember 2024-04-30 2024-04-30 0001723128 amrx:LitigationSettlementOptionOneMember amrx:CivilPrescriptionOpioidLitigationMember 2024-04-30 0001723128 amrx:LitigationSettlementOptionTwoMember amrx:CivilPrescriptionOpioidLitigationMember 2024-04-30 0001723128 amrx:LitigationSettlementOptionTwoMember amrx:CivilPrescriptionOpioidLitigationMember 2024-04-30 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2024-04-30 2024-04-30 0001723128 amrx:LitigationSettlementOptionOneMember amrx:CivilPrescriptionOpioidLitigationMember srt:MaximumMember 2024-04-30 2024-04-30 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2026-03-01 2026-03-31 0001723128 amrx:LitigationSettlementOptionTwoMember amrx:CivilPrescriptionOpioidLitigationMember 2026-03-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember srt:ScenarioForecastMember 2031-01-01 2034-12-31 0001723128 srt:ScenarioForecastMember 2031-01-01 2034-12-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2026-01-01 2026-03-31 0001723128 amrx:CivilPrescriptionOpioidLitigationMember 2026-01-29 2026-01-29 0001723128 amrx:RanitidineLitigationMember 2026-03-31 0001723128 amrx:CarickhoffV.AmnealPharmaceuticalsInc.Member 2025-05-07 2025-05-07 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2025-12-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-12-31 0001723128 amrx:AccumulatedGainLossOtherMember 2025-12-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-03-31 0001723128 amrx:AccumulatedGainLossOtherMember 2026-01-01 2026-03-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2026-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-03-31 0001723128 amrx:AccumulatedGainLossOtherMember 2026-03-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0001723128 amrx:AccumulatedGainLossOtherMember 2024-12-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0001723128 amrx:AccumulatedGainLossOtherMember 2025-01-01 2025-03-31 0001723128 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-31 0001723128 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-03-31 0001723128 amrx:AccumulatedGainLossOtherMember 2025-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimRoyaltyExpenseReleukoAndFylnetraMember 2026-01-01 2026-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:CostOfGoodsSoldDevelopmentAndCommercializationAgreementFilgrastimAndPegfilgrastimRoyaltyExpenseReleukoAndFylnetraMember 2025-01-01 2025-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2026-01-01 2026-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2025-01-01 2025-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementPegfilgrastimAutoInjectorMilestoneMember 2026-01-01 2026-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentDevelopmentAndCommercializationAgreementPegfilgrastimAutoInjectorMilestoneMember 2025-01-01 2025-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:AccountsPayableAndAccruedExpensesAndNetRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMember 2026-01-01 2026-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:AccountsPayableAndAccruedExpensesAndNetRevenueGenericDevelopmentSupplyAgreementDevelopmentActivityDeferredIncomeMember 2025-01-01 2025-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:StorageAgreementResearchAndDevelopmentMember 2026-01-01 2026-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:StorageAgreementResearchAndDevelopmentMember 2025-01-01 2025-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentParkingSpaceLeaseMember 2026-01-01 2026-03-31 0001723128 amrx:KashivBioSciencesLLCMember amrx:ResearchAndDevelopmentParkingSpaceLeaseMember 2025-01-01 2025-03-31 0001723128 amrx:ApaceKYLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2026-01-01 2026-03-31 0001723128 amrx:ApaceKYLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2025-01-01 2025-03-31 0001723128 amrx:MembersTaxReceivableAgreementMember amrx:IncreaseInTaxReceivableAgreementLiabilityMembersTaxReceivableAgreementTRALiabilityMember 2026-01-01 2026-03-31 0001723128 amrx:MembersTaxReceivableAgreementMember amrx:IncreaseInTaxReceivableAgreementLiabilityMembersTaxReceivableAgreementTRALiabilityMember 2025-01-01 2025-03-31 0001723128 amrx:AzaTechPharmaLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2026-01-01 2026-03-31 0001723128 amrx:AzaTechPharmaLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2025-01-01 2025-03-31 0001723128 amrx:KananLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2026-01-01 2026-03-31 0001723128 amrx:KananLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2025-01-01 2025-03-31 0001723128 amrx:SutariaFamilyRealtyLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2026-01-01 2026-03-31 0001723128 amrx:SutariaFamilyRealtyLLCMember amrx:InventoryAndCostOfGoodsSoldMember 2025-01-01 2025-03-31 0001723128 amrx:AvtarInvestmentsLLCMember amrx:ResearchAndDevelopmentMember 2026-01-01 2026-03-31 0001723128 amrx:AvtarInvestmentsLLCMember amrx:ResearchAndDevelopmentMember 2025-01-01 2025-03-31 0001723128 amrx:TracyPropertiesLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2026-01-01 2026-03-31 0001723128 amrx:TracyPropertiesLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2025-01-01 2025-03-31 0001723128 amrx:AvPropLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2026-01-01 2026-03-31 0001723128 amrx:AvPropLLCMember amrx:SellingGeneralAndAdministrativeOperatingLeaseMember 2025-01-01 2025-03-31 0001723128 amrx:EllodiPharmaceuticalsL.P.Member amrx:ResearchAndDevelopmentMember 2026-01-01 2026-03-31 0001723128 amrx:EllodiPharmaceuticalsL.P.Member amrx:ResearchAndDevelopmentMember 2025-01-01 2025-03-31 0001723128 amrx:RSSolutionsLLCMember amrx:PropertyPlantAndEquipmentNetMember 2026-01-01 2026-03-31 0001723128 amrx:RSSolutionsLLCMember amrx:PropertyPlantAndEquipmentNetMember 2025-01-01 2025-03-31 0001723128 amrx:AlkermesPlcMember amrx:InventoryAndCostOfGoodsSoldMember 2026-01-01 2026-03-31 0001723128 amrx:AlkermesPlcMember amrx:InventoryAndCostOfGoodsSoldMember 2025-01-01 2025-03-31 0001723128 amrx:KashivBioSciencesLLCMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:KashivBioSciencesLLCMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:AzaTechPharmaLLCSupplyAgreementMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:AzaTechPharmaLLCSupplyAgreementMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:ApacePackagingLLCPackagingAgreementMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:ApacePackagingLLCPackagingAgreementMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:MembersTaxReceivableAgreementMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:MembersTaxReceivableAgreementMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:ApaceKYLLCMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:ApaceKYLLCMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:AzaTechPharmaLLCMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:AzaTechPharmaLLCMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:AvtarInvestmentsLLCMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:AvtarInvestmentsLLCMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:KananLLCRentRelatedMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:KananLLCRentRelatedMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:TracyPropertiesLLCMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:TracyPropertiesLLCMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 amrx:CoChiefExecutiveOfficersMember us-gaap:RelatedPartyMember 2026-03-31 0001723128 amrx:CoChiefExecutiveOfficersMember us-gaap:RelatedPartyMember 2025-12-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AmnealSpecialtyPharmaSegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AvKARESegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:CorporateNonSegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AmnealSpecialtyPharmaSegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:OperatingSegmentsMember amrx:AvKARESegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:SellingGeneralAndAdministrativeExpensesMember amrx:SpecialtySegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:SellingGeneralAndAdministrativeExpensesMember amrx:SpecialtySegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:ResearchAndDevelopmentExpenseMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:ResearchAndDevelopmentExpenseMember amrx:SpecialtySegmentMember 2026-01-01 2026-03-31 0001723128 us-gaap:ResearchAndDevelopmentExpenseMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:ResearchAndDevelopmentExpenseMember amrx:SpecialtySegmentMember 2025-01-01 2025-03-31 0001723128 amrx:OrionCorporationMember us-gaap:ResearchAndDevelopmentExpenseMember amrx:AffordableMedicinesSegmentMember 2026-01-01 2026-03-31 0001723128 amrx:OrionCorporationMember us-gaap:ResearchAndDevelopmentExpenseMember amrx:AffordableMedicinesSegmentMember 2025-01-01 2025-03-31 0001723128 us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 0001723128 amrx:MSNLaboratoriesPrivateLimitedSupplyAndDistributionAgreementMember us-gaap:SubsequentEventMember 2026-04-30 2026-04-30 0001723128 srt:ScenarioForecastMember amrx:KashivBioSciencesLLCMember 2026-12-31 0001723128 srt:ScenarioForecastMember amrx:KashivBioSciencesLLCMember 2026-07-01 2026-12-31 0001723128 amrx:KashivBioSciencesLLCMember 2026-01-01 2026-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Revenue $722.5M; Operating income $141.8M.

Revenue$722.5M

Operating income$141.8M

Net income$62.3M

Free cash flow-$34.9M

EPS—

Operating cash flow-$26.7M

Financials

Income statement

Revenue$722.5M

Gross profit$320.1M

Operating income$141.8M

Net income$62.3M

Margins

Gross margin44.3%

Operating margin19.6%

Net margin8.6%

FCF margin-4.8%

Balance sheet

Total assets$3.54B

Total liabilities—

Total equity-$45.4M

Cash & equivalents$197.7M

Long-term debt$2.57B

Cash flow

Operating cash flow-$26.7M

CapEx$8.2M

Free cash flow-$34.9M

SBC$8.8M

P&L flow · revenue → net income

Highlights

▍Revenue $722.5M
▍Operating income $141.8M
▍Net margin 8.6%

Valuation FY

Market price

$18,85

Market cap

$6.09B

Enterprise valueⓘ

$8.46B

P/Eⓘ

84.5x

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

2.8x

EV / Op incomeⓘ

21.5x

EV / OCFⓘ

24.9x

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

-$2.37B

Current ratioⓘ

2.5

Debt / equityⓘ

-56.6

ROAⓘ

2.0%

ROEⓘ

-1.6%

Cash conversionⓘ

472.0%

CapEx / revenueⓘ

2.3%

SBC / revenueⓘ

1.1%

Dilution ratioⓘ

—

Revenue by segment

Business relationships

Business relationships32 disclosed relationships · 2 types · extracted from filings & disclosures

Partners1

Pfizer IncPFE.TOPartner90%Source ↗

Subsidiaries31

EX21:03d39745077fEX21:03d39745077fSubsidiarie97%

EX21:07469f24e9e4EX21:07469f24e9e4Subsidiarie97%

EX21:0a5a52141e6fEX21:0a5a52141e6fSubsidiarie97%

EX21:10b1e14bcca1EX21:10b1e14bcca1Subsidiarie97%

EX21:185dd487543dEX21:185dd487543dSubsidiarie97%

EX21:1a6ad450a834EX21:1a6ad450a834Subsidiarie97%

EX21:215634ddb879EX21:215634ddb879Subsidiarie97%

EX21:23aefc3e84c4EX21:23aefc3e84c4Subsidiarie97%

EX21:2f9f4a67dc31EX21:2f9f4a67dc31Subsidiarie97%

EX21:30f23276909cEX21:30f23276909cSubsidiarie97%

EX21:3b80d38f7686EX21:3b80d38f7686Subsidiarie97%

EX21:4293051b9130EX21:4293051b9130Subsidiarie97%

EX21:4858e45f4154EX21:4858e45f4154Subsidiarie97%

EX21:4c8edf544892EX21:4c8edf544892Subsidiarie97%

EX21:4fd18979e4c3EX21:4fd18979e4c3Subsidiarie97%

EX21:50acd3bf099aEX21:50acd3bf099aSubsidiarie97%

EX21:76cbc56631a7EX21:76cbc56631a7Subsidiarie97%

EX21:7cce37bde9d8EX21:7cce37bde9d8Subsidiarie97%

EX21:8512dc04f04cEX21:8512dc04f04cSubsidiarie97%

EX21:8de30e7634bbEX21:8de30e7634bbSubsidiarie97%

EX21:937d59b7d5acEX21:937d59b7d5acSubsidiarie97%

EX21:93b2c8158394EX21:93b2c8158394Subsidiarie97%

EX21:941dd94d43a5EX21:941dd94d43a5Subsidiarie97%

EX21:9c964d47e6acEX21:9c964d47e6acSubsidiarie97%

EX21:b2666a7af010EX21:b2666a7af010Subsidiarie97%

EX21:bab5f2f7cb35EX21:bab5f2f7cb35Subsidiarie97%

EX21:bc1c40c77674EX21:bc1c40c77674Subsidiarie97%

EX21:dcd7ebd45449EX21:dcd7ebd45449Subsidiarie97%

EX21:df638a015f4bEX21:df638a015f4bSubsidiarie97%

EX21:ef46bbba5650EX21:ef46bbba5650Subsidiarie97%

EX21:f73eb29cd3f6EX21:f73eb29cd3f6Subsidiarie97%

Supply chain

Vendors → AMRX ↔ Partners → Customers · click any node to drill

1 mention in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,99

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-07-31 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,99
Revenue	—no estimate	—no estimate	3,1B USD
Operating income	—no estimate	—no estimate	698,9M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution5 analysts

Strong buy1

Buy4

Hold0

Sell0

Strong sell0

12-month price target$20,04 · Median $21,00

Low $16,00High $23,00

Operating income · consensus698,9M USD

EPS surprise

−16,1 %

reported vs consensus · miss

Revenue surprise

−3,3 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$16,00

Mean$20,04

Median$21,00

High$23,00

Spot$18,85

+6.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin13,1 %Above median

Net Margin2,4 %Below median

ROE-158,7 %Bottom quartile

Capex / Rev2,3 %Above P75

D/E-56,63Best in class

Cash Conv4,72Best in class

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 2 525 079 sh36 exercises · 20 grants14 insiders

BUCHI J KEVINDirector · Restricted Stock Units → Class A Common StockDisposed 34 819exercise · 2026-05-07
Autor Deborah M.Director · Restricted Stock Units → Class A Common StockDisposed 34 819exercise · 2026-05-07
Yanai ShlomoDirector · Restricted Stock Units → Class A Common StockDisposed 34 819exercise · 2026-05-07
George Jeffrey P.Director · Restricted Stock Units → Class A Common StockDisposed 34 819exercise · 2026-05-07
Patel GautamDirector · Restricted Stock Units → Class A Common StockDisposed 34 819exercise · 2026-05-07
Kiely JohnDirector · Restricted Stock Units → Class A Common StockDisposed 34 819exercise · 2026-05-07
Nark Ted CDirector · Restricted Stock Units → Class A Common StockDisposed 34 819exercise · 2026-05-07
MEISTER PAUL MDirector · Restricted Stock Units → Class A Common StockDisposed 48 747exercise · 2026-05-07
Nark Ted CDirector · Restricted Stock Units → Class A Common StockAcquired 19 824grant · 2026-05-06
Kiely JohnDirector · Restricted Stock Units → Class A Common StockAcquired 19 824grant · 2026-05-06
George Jeffrey P.Director · Restricted Stock Units → Class A Common StockAcquired 19 824grant · 2026-05-06
MEISTER PAUL MDirector · Restricted Stock Units → Class A Common StockAcquired 30 837grant · 2026-05-06
Yanai ShlomoDirector · Restricted Stock Units → Class A Common StockAcquired 19 824grant · 2026-05-06
Patel GautamDirector · Restricted Stock Units → Class A Common StockAcquired 19 824grant · 2026-05-06
Autor Deborah M.Director · Restricted Stock Units → Class A Common StockAcquired 19 824grant · 2026-05-06
BUCHI J KEVINDirector · Restricted Stock Units → Class A Common StockAcquired 19 824grant · 2026-05-06
Daly Jason B.EVP, Chief Legal Officer · Restricted Stock Units → Class A Common StockDisposed 35 880exercise · 2026-03-04
Konidaris TasosExecutive Vice President & CFO · Restricted Stock Units → Class A Common StockDisposed 49 982exercise · 2026-03-04
BOYER ANDREW SExecutive Vice President · Restricted Stock Units → Class A Common StockDisposed 38 195exercise · 2026-03-04
Shah NikitaExecutive Vice President · Restricted Stock Units → Class A Common StockDisposed 35 880exercise · 2026-03-04
Patel Chirag K.Director, President & Co-CEO · Restricted Stock Units → Class A Common StockDisposed 92 593exercise · 2026-03-04
Patel ChintuDirector, Co-CEO · Restricted Stock Units → Class A Common StockDisposed 92 593exercise · 2026-03-04
Patel ChintuDirector, Co-CEO · Restricted Stock Units → Class A Common StockDisposed 59 931exercise · 2026-03-03
Patel ChintuDirector, Co-CEO · Performance-Based Restricted Stock Units → Class A Common StockDisposed 733 944exercise · 2026-03-03
Daly Jason B.EVP, Chief Legal Officer · Restricted Stock Units → Class A Common StockDisposed 22 645exercise · 2026-03-03

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Market Cap
market_price * shares_outstanding_diluted

Source documents

Amneal Pharmaceuticals, Inc. company facts · 2026-07-31
Amneal Pharmaceuticals, Inc. 10-Q 2026-05-07 · 2026-07-31
Amneal Pharmaceuticals, Inc. 10-K 2026-02-27 · 2026-07-31
Amneal Pharmaceuticals, Inc. 10-Q 2025-11-06 · 2026-07-31
Amneal Pharmaceuticals, Inc. 10-Q 2025-08-07 · 2026-07-31
8-K (sec_8k_material) on AMRX · 2026-07-31
Amneal Pharmaceuticals Inc Market data — analyst estimates · 2026-07-31
Amneal Pharmaceuticals Inc Market data — ESG · 2026-07-31
Amneal Pharmaceuticals, Inc. HA canonical relationships · 2026-07-31

Ownership & reference

Top holders

Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$71M
First Trust Advisors L.P.Investment Managers · as of 2026-03-310,01 %$9M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$12M
Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$22M
Invesco QQQ TrustFunds · as of 2026-03-310,01 %$40M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,01 %$23M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$11M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$36M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$27M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$6M
Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$7M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$57M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$58M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$226M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$84M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$9M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$21M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$11M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$10M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$5M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$72M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$5M
Jennison Associates LLCInvestment Managers · as of 2026-03-310,00 %$2M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$2M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$10M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$1M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 6 sellsnet -$4,1M14 insiders · last 365d

Autor Deborah M.Director · Class A Common StockSold 34 819 @ $12,94$451K · 2026-05-11
BUCHI J KEVINDirector · Class A Common StockOther 34 819 · 2026-05-07
Autor Deborah M.Director · Class A Common StockOther 34 819 · 2026-05-07
George Jeffrey P.Director · Class A Common StockOther 34 819 · 2026-05-07
Patel GautamDirector · Class A Common StockOther 34 819 · 2026-05-07
Yanai ShlomoDirector · Class A Common StockOther 34 819 · 2026-05-07
Kiely JohnDirector · Class A Common StockOther 34 819 · 2026-05-07
MEISTER PAUL MDirector · Class A Common StockOther 48 747 · 2026-05-07
Nark Ted CDirector · Class A Common StockOther 34 819 · 2026-05-07
Daly Jason B.EVP, Chief Legal Officer · Class A Common StockOther 35 880 · 2026-03-04
Patel ChintuDirector, Co-CEO · Class A Common StockOther 92 593 · 2026-03-04
Patel ChintuDirector, Co-CEO · Class A Common StockOther 28 983 @ $13,30$385K · 2026-03-04
Patel Chirag K.Director, President & Co-CEO · Class A Common StockOther 92 593 · 2026-03-04
Patel Chirag K.Director, President & Co-CEO · Class A Common StockOther 37 825 @ $13,30$503K · 2026-03-04
Daly Jason B.EVP, Chief Legal Officer · Class A Common StockOther 15 580 @ $13,30$207K · 2026-03-04
Konidaris TasosExecutive Vice President & CFO · Class A Common StockOther 43 982 · 2026-03-04
Konidaris TasosExecutive Vice President & CFO · Class A Common StockOther 22 035 @ $13,30$293K · 2026-03-04
BOYER ANDREW SExecutive Vice President · Class A Common StockOther 38 195 · 2026-03-04
BOYER ANDREW SExecutive Vice President · Class A Common StockOther 19 136 @ $13,30$255K · 2026-03-04
Shah NikitaExecutive Vice President · Class A Common StockOther 35 880 · 2026-03-04
Shah NikitaExecutive Vice President · Class A Common StockOther 17 976 @ $13,30$239K · 2026-03-04
Patel ChintuDirector, Co-CEO · Class A Common StockOther 733 944 · 2026-03-03
Patel ChintuDirector, Co-CEO · Class A Common StockOther 59 931 · 2026-03-03
BOYER ANDREW SExecutive Vice President · Class A Common StockOther 39 252 · 2026-03-03
Konidaris TasosExecutive Vice President & CFO · Class A Common StockOther 229 817 @ $13,31$3,1M · 2026-03-03

Short positioning

8.1Mshares short+3.6% vs prior

4.5days to cover

59.6%short of daily vol

1.8Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

AMRXCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskMedium

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Source documents mention dilution or offering risk.

Relationship graph

This companySectorPartnersSubsidiaries

Evidence & claims

From filings & derived data

Operating income (annual): USD 394.1MUnknown
Total assets (annual): USD 3.68BUnknown
Current assets (annual): USD 1.91BUnknown
Net income (annual): USD 72.06MUnknown
R&D expense (annual): USD 186.18MUnknown
Pre-tax income (annual): USD 139.21MUnknown
Cash & equivalents (annual): USD 282.03MUnknown
Current liabilities (annual): USD 881.63MUnknown
Shareholders' equity (annual): USD -70.79MUnknown
Long-term debt (annual): USD 2.57BUnknown
Gross profit (annual): USD 1.11BUnknown
EPS (basic) (annual): USD-PER-SHARES 0Unknown
EPS (diluted) (annual): USD-PER-SHARES 0Unknown
Revenue (annual): USD 3.02BUnknown
Capex (annual): USD 70.06MUnknown
Cost of revenue (annual): USD 1.91BUnknown
Operating cash flow (annual): USD 339.99MUnknown
Capex (annual): USD 51.92MUnknown
Operating cash flow (annual): USD 295.1MUnknown
Cash & equivalents (annual): USD 110.55MUnknown
Shareholders' equity (annual): USD -109.27MUnknown
Current liabilities (annual): USD 1.13BUnknown
Operating income (annual): USD 249.33MUnknown
Revenue (annual): USD 2.79BUnknown

Showing 24 of 34 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-31 04:36 UTCFILINGMaterial 8-K

2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-30EVENTQ2 2026 earnings (expected) estimated date

2026-05-11 00:00 UTCINSIDER25 insider transactions — 2026-05 · net sell $451k 16 derivative

2026-05-11INSIDERAutor Deborah M. sold 34.8k sh Class A Common Stock — Director ~$451k

2026-05-07FILING10-Q filing →

2026-05-07FILING8-K filing →

2026-05-07INSIDERBUCHI J KEVIN transacted 34.8k sh Class A Common Stock — Director

2026-05-07INSIDERAutor Deborah M. transacted 34.8k sh Class A Common Stock — Director

2026-05-07INSIDERGeorge Jeffrey P. transacted 34.8k sh Class A Common Stock — Director

2026-05-07INSIDERPatel Gautam transacted 34.8k sh Class A Common Stock — Director

2026-05-07INSIDERYanai Shlomo transacted 34.8k sh Class A Common Stock — Director

2026-05-07INSIDERKiely John transacted 34.8k sh Class A Common Stock — Director

2026-05-07INSIDERMEISTER PAUL M transacted 48.7k sh Class A Common Stock — Director

2026-05-07INSIDERNark Ted C transacted 34.8k sh Class A Common Stock — Director

2026-05-07INSIDERAutor Deborah M. disposed of 34.8k sh Restricted Stock Units — Director

2026-05-07INSIDERBUCHI J KEVIN disposed of 34.8k sh Restricted Stock Units — Director

2026-05-07INSIDERNark Ted C disposed of 34.8k sh Restricted Stock Units — Director

2026-05-07INSIDERGeorge Jeffrey P. disposed of 34.8k sh Restricted Stock Units — Director

2026-05-07INSIDERPatel Gautam disposed of 34.8k sh Restricted Stock Units — Director

2026-05-07INSIDERYanai Shlomo disposed of 34.8k sh Restricted Stock Units — Director

2026-05-07INSIDERKiely John disposed of 34.8k sh Restricted Stock Units — Director

2026-05-07INSIDERMEISTER PAUL M disposed of 48.7k sh Restricted Stock Units — Director

2026-05-06INSIDERPatel Gautam acquired 19.8k sh Restricted Stock Units — Director

2026-05-06INSIDERGeorge Jeffrey P. acquired 19.8k sh Restricted Stock Units — Director

2026-05-06INSIDERKiely John acquired 19.8k sh Restricted Stock Units — Director

2026-05-06INSIDERNark Ted C acquired 19.8k sh Restricted Stock Units — Director

2026-05-06INSIDERMEISTER PAUL M acquired 30.8k sh Restricted Stock Units — Director

2026-05-06INSIDERYanai Shlomo acquired 19.8k sh Restricted Stock Units — Director

2026-05-06INSIDERAutor Deborah M. acquired 19.8k sh Restricted Stock Units — Director

2026-05-06INSIDERBUCHI J KEVIN acquired 19.8k sh Restricted Stock Units — Director

2026-04-22FILING8-K filing →

2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 722.5M · Net USD 62.3M

2026-03-25FILINGDEFINITIVE PROXY STATEMENT →

2026-03-04 00:00 UTCINSIDER90 insider transactions — 2026-03 · net sell $23.1M 38 derivative

2026-03-04INSIDERDaly Jason B. transacted 35.9k sh Class A Common Stock — EVP, Chief Legal Officer

2026-03-04INSIDERPatel Chintu transacted 92.6k sh Class A Common Stock — Director, Co-CEO

2026-03-04INSIDERPatel Chintu transacted 29.0k sh Class A Common Stock — Director, Co-CEO ~$385k

Showing the 40 most recent of 67 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread